Major Milestone Reached in PSC Cancer Risk Study
Major Milestone Reached in PSC Cancer Risk Study
Dr Rodrigo Motta
This important research project, funded by PSC Support, has successfully completed a critical sample collection phase, bringing scientists closer to developing a non-invasive method for the early detection of bile duct cancer (cholangiocarcinoma, or CCA)) in people with PSC. This work directly aligns with PSC Support’s strategy to accelerate the development of tools that can detect cancers early and with certainty.
What is the progress of the DNA methylation study?
The research team, led by Dr. Rodrigo Motta at the University of Oxford, has successfully completed the extensive collection of plasma samples. A total of 100 plasma samples from five different patient cohorts have now been collected, marking a significant step towards the analysis phase of the project. This is a vital stage, as it ensures the researchers have a broad and relevant set of biological material to investigate. If you’ve ever donated a sample to research during a procedure, thank you. This kind of research cannot take place without such samples.
Which patient samples have been collected?
The comprehensive collection of samples is designed to allow for detailed comparison, helping researchers to pinpoint changes that are specific to the development of CCA in people with PSC. The 100 samples collected between April and September 2025 were separated into five distinct groups:
- 20 samples from patients with cholangiocarcinoma (bile duct cancer).
- 20 samples from PSC patients considered to be at high risk of bile duct cancer.
- 20 samples from PSC patients considered to be at low risk of bile duct cancer.
- 20 samples from patients with ulcerative colitis.
- 20 healthy control samples.
What is the next step for the research?
The next phase involves transferring the samples to the University of Oxford for advanced analysis. The team will be using a new, state-of-the-art technology to study subtle changes around the DNA, known as DNA methylation. This non-invasive method is highly sensitive and efficient, enabling researchers to gain extensive insight from very small volumes of blood. Dr. Motta confirmed this progress:
“We collected and separated plasma samples from 100 patients between April and September 2025... These samples are going to be analysed using a new technology developed at the University of Oxford. This technology allows us to study changes around the DNA without damaging it too much, therefore even small samples (3mL) can give us plenty of information to look for early signs of cancer.” Dr. Motta.
As part of our Mission 2030 research strategy, this work directly addresses the critical need for a reliable screening method for people with PSC. The ultimate goal of this project is to develop a reliable, non-invasive blood test that can be used to screen for cancer in people with PSC, helping to catch complications much earlier.
Turning Ambition into Action in 2026:
Our Fortnight in Focus
At PSC Support, we want a world without PSC. We work tirelessly behind the scenes to drive research and improve lives. Here is a snapshot of what we've been up to:
Organisational excellence: We simplified our personal data consent process and streamlined how we record patient stories to ensure that the lived experiences of our community are captured accurately and securely to inform future work.
Progressing Research: We coordinated a series of upcoming meetings with international researchers and pharmaceutical companies, which supports better informed decisions for people with PSC, research, or care. This groundwork helps keep PSC research focused on the primary needs of the patient community.
Progressing Research: We reviewed and contributed to scientific abstracts and posters for the upcoming EASL international liver congress, which strengthens the quality of future research for people with PSC, research, or care.
Progressing Research: We engaged with the MHRA to prepare for the upcoming national consultation on rare disease therapies, representing PSC patients in the wider community. Maintaining this direct dialogue ensures our organisation is prepared to respond formally and protect the interests of those living with PSC
Improving Care: We presented about what it is really like to live with PSC to gastroenterologists This first-hand insight equips healthcare professionals to better understand the day-to-day challenges of PSC.
Income Generation: We secured a place in the prestigious Big Give Small Charity Week match-funding campaign, so that we can maximise future donations from our supporters as every donation between 22 and 29 June will be doubled!
Progressing Research: We recruiting for a research and advocacy officer to expand our core team. This additional capacity ensures we can better support scientific studies and represent the patient voice at every level.